The state of cancer care in Russia: prostate cancer (С61). Observed and relative survival of patients with prostate cancer. Modern treatment options. Part 2. (clinical-population study)
Pharmacy Formulas · 30.04.2026 · 7 (4) · 32-43
DOI: 10.17816/phf699325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy Formulas, online erschienen am 30.04.2026. Verfasst von Vakhtang M. Merabishvili und 6 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
This study is dedicated to analyzing the survival dynamics of patients with prostate cancer (PCa) in the Northwestern Federal District of the Russian Federation over a 25-year period (2000–2024). The relevance of the work is driven by the high growth rate of PCa incidence and the need for an objective assessment of the effectiveness of oncological care at the population level. The aim of the research was to calculate the observed and relative survival rates of patients, as well as to evaluate modern anti-tumor therapy options. The study was based on data from the Population Cancer Registry (PCR) of the Northwestern Federal District of the RF. From a total dataset of 1.6 million observations, a verified sample of 76,206 PCa cases was formed. Calculations were performed in accordance with international standards of the Eurocare program, with authors’ modifications. The analysis demonstrated significant progress in the treatment of PCa patients. Over the studied period, the average one-year observed survival rate increased by 20.2%, reaching 89.4% (relative – 93.5%). The five-year observed survival rate grew from 42.4% (period 2000–2004) to 57.6% (2010–2014), representing a 35.8% increase; the five-year relative survival rate reached 75.3%. One-year mortality decreased by more than half, from 25.6% to 10.6%. Regarding age-related aspects, it was found that the relative one-year survival rates remained consistently high both in the group under 60 years (94.2%) and among older individuals (93.4%), confirming the effectiveness of modern treatment protocols across all age categories.
Zitieren
APA
Merabishvili, V. M., Krivonosov, D. I., Berkut, M. V., Startsev, V. Y., Yurkova, Y. P., Nosov, A. K., & Efimov, S. N. (2026). The state of cancer care in Russia: prostate cancer (С61). Observed and relative survival of patients with prostate cancer. Modern treatment options. Part 2. (clinical-population study). Pharmacy Formulas, 7(4), 32-43. https://doi.org/10.17816/phf699325
Vancouver
Merabishvili VM, Krivonosov DI, Berkut MV, Startsev VY, Yurkova YP, Nosov AK, et al. The state of cancer care in Russia: prostate cancer (С61). Observed and relative survival of patients with prostate cancer. Modern treatment options. Part 2. (clinical-population study). Pharmacy Formulas. 2026;7(4):32-43. doi:10.17816/phf699325
BibTeX
@article{Merabishvili2026,
author = {Merabishvili, Vakhtang M. and Krivonosov, Dmitri I. and Berkut, Maria V. and Startsev, Vladimir Y. and Yurkova, Yulia P. and Nosov, Alexander K. and Efimov, Sergey N.},
title = {The state of cancer care in Russia: prostate cancer (С61). Observed and relative survival of patients with prostate cancer. Modern treatment options. Part 2. (clinical-population study)},
journal = {Pharmacy Formulas},
year = {2026},
volume = {7},
number = {4},
pages = {32--43},
doi = {10.17816/phf699325}
}
EUVIMED